AR230954A1 - Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado - Google Patents

Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado

Info

Publication number
AR230954A1
AR230954A1 AR291580A AR29158082A AR230954A1 AR 230954 A1 AR230954 A1 AR 230954A1 AR 291580 A AR291580 A AR 291580A AR 29158082 A AR29158082 A AR 29158082A AR 230954 A1 AR230954 A1 AR 230954A1
Authority
AR
Argentina
Prior art keywords
viii
employee
pro
compact
separation
Prior art date
Application number
AR291580A
Other languages
English (en)
Spanish (es)
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23288328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR230954(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Application granted granted Critical
Publication of AR230954A1 publication Critical patent/AR230954A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AR291580A 1981-12-14 1982-12-14 Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado AR230954A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/330,105 US4361509A (en) 1981-12-14 1981-12-14 Ultrapurification of factor VIII using monoclonal antibodies

Publications (1)

Publication Number Publication Date
AR230954A1 true AR230954A1 (es) 1984-08-31

Family

ID=23288328

Family Applications (1)

Application Number Title Priority Date Filing Date
AR291580A AR230954A1 (es) 1981-12-14 1982-12-14 Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado

Country Status (10)

Country Link
US (1) US4361509A (fr)
EP (1) EP0083483B2 (fr)
JP (4) JPH0723321B2 (fr)
AR (1) AR230954A1 (fr)
AU (1) AU545770B2 (fr)
CA (1) CA1208130A (fr)
DE (3) DE3280469T2 (fr)
LU (1) LU88333I2 (fr)
NL (1) NL930118I2 (fr)
WO (1) WO1983002114A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
CA1209907A (fr) * 1982-04-12 1986-08-19 Richard M. Bartholomew Methode de purification par affinite ayant recours a des anticorps monoclonaux
US4397841A (en) * 1982-06-28 1983-08-09 Monsanto Company Production of blood coagulation factor VIII:C
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4614795A (en) * 1982-08-05 1986-09-30 University Of Rochester Deglycosylated Human Factor VIII:C
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US5614500A (en) * 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
EP0118256B1 (fr) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbant et procédé de récupération de protéines dépendantes de la vitamine-K utilisant cet adsorbant
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
NO167533C (no) * 1983-03-31 1991-11-13 Scripps Clinic Res Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
JPS61500226A (ja) * 1983-10-28 1986-02-06 ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド コンホメ−ション特異性抗体を用いる血液凝固タンパク質の精製および単離法
US6258938B1 (en) 1983-10-28 2001-07-10 Ne Medical Center Hospital, Inc. Method for the purification and isolation of blood clotting proteins using conformation specific antibodies
WO1985001961A1 (fr) * 1983-10-28 1985-05-09 Genetics Institute Production du facteur viii et des produits relatifs
US4945041A (en) * 1983-11-17 1990-07-31 Board Of Regents Monoclonal antibodies for Mycoplasma pneumoniae and use for diagnosis of pneumonia
US4469630A (en) * 1983-11-25 1984-09-04 J. T. Baker Chemical Co. Purification of monoclonal antibodies
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4568488A (en) * 1984-01-11 1986-02-04 Lee Huang Sylvia Reverse immunoaffinity chromatography purification method
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
EP0152746B1 (fr) * 1984-01-12 1991-08-14 Chiron Corporation Lignes de cellules hybridomes et anticorps monoclonaux contre le facteur VIII C
US4716117A (en) * 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4604235A (en) * 1984-05-23 1986-08-05 J. T. Baker Chemical Company Purification of monoclonal antibodies
FI852866A7 (fi) * 1984-07-27 1986-01-28 Meloy Laboratories Inc Yhdistelmä-tekijä VIII-R.
US4693985A (en) * 1984-08-21 1987-09-15 Pall Corporation Methods of concentrating ligands and active membranes used therefor
EP0182448A3 (fr) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Production de facteur VIII et produits apparentés
FR2570276B1 (fr) * 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US4560504A (en) * 1984-12-06 1985-12-24 Uop Inc. Carboxyl anchored immobilized antibodies
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
CA1297815C (fr) * 1985-06-07 1992-03-24 Barry S. Coller Anticorps monoclonal bloquant le fibrinogene
GB8516570D0 (en) * 1985-07-01 1985-08-07 Common Services Agency For The Coupling reaction
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
GB2178533B (en) * 1985-07-22 1989-07-19 Asahi Chemical Ind Analytical method of enzyme precursors and device therefor
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
CA1339946C (fr) * 1987-03-31 1998-07-07 Michael J. Griffith Methode d'ultrapurification pour les polypeptides
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
US4831118A (en) * 1987-08-07 1989-05-16 Scripps Clinic And Research Foundation Flouroplastic immunoaffinity columns for purification of blood proteins
IL88309A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides for use in the purification of factor viii
ATE112287T1 (de) * 1987-12-21 1994-10-15 Miles Inc Faktor viii- gelfiltration.
JP2761881B2 (ja) * 1988-03-10 1998-06-04 チッソ株式会社 抗体を固定化したアフイニテイクロマトグラフイ用担体
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
DE3904354A1 (de) 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
US5252711A (en) * 1989-06-01 1993-10-12 The Gillette Company Monoclonal antibodies useful in deodorizing skin and antibody fragments thereof
WO1990015992A1 (fr) * 1989-06-15 1990-12-27 Smith William I Jr Procede et appareil rendant inactifs les agents infectieux dans les fluides biologiques, et resistant a la coagulation de ceux-ci
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5321123A (en) * 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406867B (de) * 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US5994310A (en) * 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
US7879621B2 (en) * 2003-05-08 2011-02-01 Phynexus, Inc. Open channel solid phase extraction systems and methods
DE10246125A1 (de) * 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
CN103170309B (zh) * 2013-03-12 2014-10-29 中国农业大学 一种莱克多巴胺抗体免疫亲和层析柱及其应用
CN110382547B (zh) * 2016-12-14 2023-06-06 盼展生物技术有限公司 抗凝血因子viii抗体及其用途
CA3079956C (fr) 2017-10-27 2023-06-27 Green Cross Holdings Corporation Procede de preparation d'une composition contenant un facteur 8 capable de controler la teneur en facteur von willebrand (facteur vw) et facteurvon willebrand
CA3094644A1 (fr) 2018-03-21 2019-09-26 Baxalta Incorporated Separation de vwf et de propeptide de vwf par des procedes chromatographiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
FR2363577A1 (fr) * 1976-09-03 1978-03-31 Recherches Hematologiques Procede simplifie pour preparer avec un rendement eleve du concentre de facteur antihemophilique pur
US4137223A (en) * 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
CA1074698A (fr) * 1977-12-19 1980-04-01 Gail A. Rock Methode pour augmenter la production de facteur antihemophilique viii dans le sang et le plasma
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
EP0083483B2 (fr) 1997-09-17
CA1208130A (fr) 1986-07-22
WO1983002114A1 (fr) 1983-06-23
JP2554848B2 (ja) 1996-11-20
JPH0784480B2 (ja) 1995-09-13
DE3280469D1 (de) 1995-08-31
LU88333I2 (fr) 1994-05-04
JPH0616700A (ja) 1994-01-25
JPH0723321B2 (ja) 1995-03-15
DE19375054I2 (de) 2005-05-12
JPH08301787A (ja) 1996-11-19
AU9145682A (en) 1983-06-23
NL930118I2 (nl) 1995-05-16
DE3278402D1 (de) 1988-06-01
AU545770B2 (en) 1985-08-01
EP0083483B1 (fr) 1988-04-27
JPH07238034A (ja) 1995-09-12
NL930118I1 (nl) 1993-11-01
DE3280469T2 (de) 1996-01-04
JPS58131918A (ja) 1983-08-06
CA1251152C (fr) 1989-03-14
US4361509A (en) 1982-11-30
EP0083483A1 (fr) 1983-07-13

Similar Documents

Publication Publication Date Title
AR230954A1 (es) Un metodo mejorado de separacion y concentracion de la proteina de actividad pro-coagulante viii:c a partir de un complejo de factor viii que contiene viii:c y viii:rp y un inmunoabsorbente empleado
DE3682690D1 (de) Verfahren zur analyse von subpopulationen von blutzellen.
ATE210826T1 (de) Verfahren zur bestimmung von cyclooxygenase-1- aktivität
DE3578569D1 (de) Trennung von lymphocyten und monocyten aus blutproben.
DK159000C (da) Indretning til mejetaersker til at sprede avner
ES555261A0 (es) Un metodo para detectar la presencia de un inhibidor de anticuerpos de factor viii humano en una muestra
FI933322A7 (fi) Menetelmä lääketieteellisen näytteen ainesosan analysoimiseksi
DE3168691D1 (en) Immunoassay of proteins
DE3872754D1 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
IT1199877B (it) Assorbente igienico e procedimento per la sua fabbricazione
IT1193728B (it) Struttura per la confezione singola di assorbenti igienici e metodo per la sua realizzazione
DE3378075D1 (en) A potentiometric analysis system and method of using such system to analyse blood
DE3650147D1 (de) Verfahren zur bestimmung menschlicher lungenoberflächenaktiver substanz und reagenziensatz dazu.
IT1142029B (it) Preparato cosmetico e procedimento per la sua preparazione
FR2556720B1 (fr) Derives de l'amidine et tonicardiaques les contenant
GB8330237D0 (en) Quantitative analysis of substances
FI895215A7 (fi) Menetelmä antitrombiini III:n biologisen aktiivisuuden määrittämiseksi ja reagenssi sitä varten
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
FI883489L (fi) Lymfosyyttien tunnusmerkillinen potentiaalille herkkien aineiden sitominen
PT87036A (pt) Conjunto de analise para deteccao de antigenes de hepatite e de anticorpos de sida
KR860005021A (ko) HBc 항원의 정재방법 및 정제된 HBc 항원을 이용한 HBc 항체의 측정방법
FI841145A7 (fi) Menetelmä hemoglobiinipitoisuuden kvantitatiiviseksi määrittämiseksi biologisessa näytteessä.
NO174056C (no) Fremgangsmåte ved separasjon av aktivert humant protein-C
NO171170C (no) Humant protein-c antistoff
GB2118301B (en) Multilayer element for quantitative analysis of protein